The objective of this study is to incorporate serum Ferroxidase as a surrogate marker of pulmonary tuberculosis (PTB) Fifty patients with PTB whose sputum samples were positive for acid fast bacilli (Group I) and 50 subject who were completely treated for PTB (Group II) were compared with 50 healthy controls. The difference, were similarly found between male and female Group I subject and Controls in serem ferroxidase levels. Serum Ferroxidase was measured by end point method of Ozcan Erel at 600nm. Mean ± SD of serum Ferroxidase in control, Group I and Group II were 800.87±130IU/L, 1616.02±216 IU/L and 851.12±201 IU/L respectively. Serum Ferroxidase in Group I was significantly higher as compared to control (P<0.001) whereas in Group II it was not significant when compared with control. Serum Ferroxidase which was higher in newly diagnosed PTB patients falls back to normal level on complete treatment with ATT. Hence serum Ferroxidase activity of ceruloplasmin can be used both as a diagnostic and prognostic marker of PTB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.